Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

Since romidepsin has shown promise in the treatment of T-cell lymphomas, we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health. The endpoints included histone H3 acetylati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bates, Susan E., Zhan, Zhirong, Steadman, Kenneth, Obrzut, Tomasz, Luchenko, Victoria, Frye, Robin, Robey, Robert W., Turner, Maria, Gardner, Erin R., Figg, William D., Steinberg, Seth M., Ling, Alex, Fojo, Tito, To, Kin Wah, Piekarz, Richard L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838427/
https://ncbi.nlm.nih.gov/pubmed/19874311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07954.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares